期刊
LANCET
卷 385, 期 9971, 页码 884-898出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(14)60456-6
关键词
-
资金
- US National Institutes of Neurological Diseases and Stroke (NINDS) [NS-20253, NS-43209, NS-45911, NS-78333]
- US Department of Defense
- CURE Foundation
- UCB Pharma
- Heffer Family Medical Foundation
- Segal Family Foundation
- Lundbeck
- European Union
- Italian Medicines Agency
- Italian Ministry of Health
- Italian Ministry for Education, University and Research
- C Mondino National Neurological Institute
- GW Pharma
- Upsher-Smith
- Eisai
- GSK
- Medichem
- Sun Pharma
- Supernus
- Vertex
- Viropharma
- French Ministry of Health (PHRC)
- French Agency for Research (ANR)
- Cyberonics
- Medtronic
- Stockholm County Council
- AFA Insurance
- CURE
- UCB
- Sanofi-Aventis
- Novartis
- Bial
Epilepsy affects 65 million people worldwide and entails a major burden in seizure-related disability, mortality, comorbidities, stigma, and costs. In the past decade, important advances have been made in the understanding of the pathophysiological mechanisms of the disease and factors affecting its prognosis. These advances have translated into new conceptual and operational definitions of epilepsy in addition to revised criteria and terminology for its diagnosis and classification. Although the number of available antiepileptic drugs has increased substantially during the past 20 years, about a third of patients remain resistant to medical treatment. Despite improved effectiveness of surgical procedures, with more than half of operated patients achieving long-term freedom from seizures, epilepsy surgery is still done in a small subset of drug-resistant patients. The lives of most people with epilepsy continue to be adversely affected by gaps in knowledge, diagnosis, treatment, advocacy, education, legislation, and research. Concerted actions to address these challenges are urgently needed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据